+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dexlansoprazole"

Proton Pump Inhibitors Global Market Report 2024 - Product Thumbnail Image

Proton Pump Inhibitors Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
Gastric Ulcers - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Ulcers - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 57 Pages
  • Global
From
From
Peptic Ulcers - Pipeline Review, H1 2020 - Product Thumbnail Image

Peptic Ulcers - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 65 Pages
  • Global
From
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Dexlansoprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and other gastrointestinal disorders. It is a prescription medication that works by reducing the amount of acid produced in the stomach. It is available in both immediate-release and delayed-release formulations. Dexlansoprazole is also used to treat erosive esophagitis, a condition in which the lining of the esophagus is damaged by stomach acid. It is also used to treat ulcers, and to prevent ulcers from forming in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Dexlansoprazole is a popular choice for treating GERD and other gastrointestinal disorders due to its effectiveness and relatively low side effects. It is generally well tolerated and has few drug interactions. The Dexlansoprazole market is highly competitive, with many companies offering their own formulations of the drug. Some of the major players in the market include Takeda Pharmaceuticals, AstraZeneca, Pfizer, and Sun Pharmaceuticals. Show Less Read more